CB-839
99%
- Product Code: 67260
CAS:
1439399-58-2
| Molecular Weight: | 571.5700000000001 g./mol | Molecular Formula: | C₂₆H₂₄F₃N₇O₃S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD28167826 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
CB-839 is primarily utilized in the field of cancer research and treatment. It functions as a glutaminase inhibitor, targeting and blocking the activity of the enzyme glutaminase, which is crucial for cancer cell metabolism. By inhibiting this enzyme, CB-839 disrupts the ability of cancer cells to utilize glutamine, an essential nutrient for their growth and survival. This makes it particularly effective in targeting cancers that are highly dependent on glutamine, such as certain types of triple-negative breast cancer, lung cancer, and renal cell carcinoma. CB-839 is often investigated in combination with other therapies, including chemotherapy and immunotherapy, to enhance its efficacy and improve patient outcomes. Its role in clinical trials continues to expand as researchers explore its potential in treating various malignancies and overcoming drug resistance in cancer cells.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | yellow solid |
| PURITY | 98.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | €216.86 |
+
-
|
CB-839
CB-839 is primarily utilized in the field of cancer research and treatment. It functions as a glutaminase inhibitor, targeting and blocking the activity of the enzyme glutaminase, which is crucial for cancer cell metabolism. By inhibiting this enzyme, CB-839 disrupts the ability of cancer cells to utilize glutamine, an essential nutrient for their growth and survival. This makes it particularly effective in targeting cancers that are highly dependent on glutamine, such as certain types of triple-negative breast cancer, lung cancer, and renal cell carcinoma. CB-839 is often investigated in combination with other therapies, including chemotherapy and immunotherapy, to enhance its efficacy and improve patient outcomes. Its role in clinical trials continues to expand as researchers explore its potential in treating various malignancies and overcoming drug resistance in cancer cells.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :